Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer.

摘要: Purpose: Irinotecan hydrochloride shows a strong activity against gastric cancer and colorectal cancer, while combined therapy with irinotecan cisplatin is useful for cancer. However, myelosuppression diarrhea are still dose-limiting factors. To reduce such toxicities to enable be performed on an outpatient basis, we tested the effect of divided administration cisplatin. Methods: (60 mg/m2) plus (30 were administered days 1 15 every 4 weeks 13 patients advanced Treatment was continued if leukocyte count ≥3000/mm3, platelet ≥100,000 /mm3, grade 0 confirmed. Doses reduced 3–4 hematological toxicity 2 or higher nonhematological occurred. Results: The major leukopenia (neutropenia), but not observed. response rate 41.7% (5/12 evaluable patients) 36.7% (4/11 patients). median survival time 313 (range 29–920 days) 490 83–1184+ patients. Conclusion: Fortnightly (with dose) seems regimen gastrointestinal It reduces maintaining good antitumor effect.